Insulet (PODD)
(Delayed Data from NSDQ)
$204.42 USD
+11.84 (6.15%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $202.65 -1.77 (-0.87%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$204.42 USD
+11.84 (6.15%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $202.65 -1.77 (-0.87%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum C VGM
Zacks News
Lilly's Diabetes Drugs Meet Endpoints in Phase III Studies
by Zacks Equity Research
Lilly's (LLY) Jardiance and Humulin, being evaluated in separate phase III studies, meet primary endpoint of reduction in blood sugar level.
Insulet (PODD) Shows Strength: Stock Adds 7.1% in Session
by Zacks Equity Research
Insulet Corporation (PODD) moved big last session, as its shares jumped over 7% on the day.
Should You Make a Bet on the Healthcare Stocks?
by Tracey Ryniec
The healthcare industry is much more than Obamacare and drug prices as many companies are using new technologies to create breakthroughs in medicine.
The Zacks Analyst Blog Highlights: Sucampo Pharmaceuticals, Insulet, Western Refining, PennyMac Mortgage Investment Trust and Extended Stay America
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Sucampo Pharmaceuticals, Insulet, Western Refining, PennyMac Mortgage Investment Trust and Extended Stay America
5 Underperformers of 2016: Turnaround Story in 2017?
by Zacks Equity Research
Based on strong fundamentals, strategic implementation, planned execution, and certain positive catalysts, these five stocks carry a huge upside potential and a high probability of outperforming the S&P 500 market index in the coming days.